My IDSA Contact Us
IDSA NewsPrint-Friendly Newsletter
Forward to a Friend
Search Back Issues
 
Education & Training Resources Practice Guidelines Journals & Publications Policy & Advocacy Meetings About IDSA
July/August 2012
Your Colleagues
Check Out “My IDSA” for Latest Member News

Find the latest membership news on “My IDSA” on the IDSA website, including:

  • a reminder about voting for the IDSA and HIVMA Boards of Directors
  • the 2012 Medical Scholars Program recipients
  • members newly elected as fellows of IDSA
  • new IDSA members

Are you a member on the move? Do you know someone who is? Contact Stephanie Cox at scox@idsociety.org so that we can announce it to our membership.
How useful is this article?

< Previous Article | Next Article >

Post a comment

Your name:

Your comment:


Patient Care and Science
CDC No Longer Recommends Cefixime as First-Line Treatment for Gonorrhea
Reminder: Registration, Reporting Requirements for Clinical Trials Investigators
Drug Approvals, Recalls, Adverse Events Update
Global ID
U.S. Pledges to Release Blueprint for “AIDS-Free Generation”
Haitian Prison Highlights TB Challenges Despite Improved Diagnostics
Q&A: Global Fund General Manager Gabriel Jaramillo
HIV Treatment as Prevention Among Drug Users
Policy and Advocacy
FDA Takes Steps Towards More Judicious Antimicrobial Use in Animals
IDSA Applauds Finalized Guidelines for HCV Screening
IDSA Comments on Upcoming HHS Antibiotic Incentives Study
Your Colleagues
Check Out “My IDSA” for Latest Member News
Education & Resources
CID Seeks Applicants for Assistant Deputy Editor Position
Updated IDSA Lyme Disease Online Course Offers CME Credit
Top Stories
IDWeek 2012: See you in San Diego!
H3N2v Information for Clinicians
A Look Back at the AIDS 2012 Conference
IDSA Journal Club

IDSA | 1300 Wilson Blvd., Suite 300 | Arlington, VA 22209 | Phone: (703) 299-0200
To ensure delivery, please add 'info@idsociety.org' to your email address book or Safe Sender List.
If you are still having problems receiving our communications,
see our white-listing page for more details.